On June 11, 2026, NeuroSense Therapeutics Ltd. announced it was granted a patent in South Korea covering the PrimeC composition for the treatment of Amyotrophic Lateral Sclerosis (ALS). The company is a biotechnology firm that develops therapeutic candidates for neurological disorders.
